Immunogenicity of the COVID-19 Two-Vaccination Series Among Hematologic Malignancies: Report of Three Cases of Breakthrough Infection혈액암 중 COVID-19 2회 접종 시리즈의 면역원성: 3건의 돌발 감염 사례 보고Case Reports Published on 2022-01-012022-09-12 Journal: Cancer control : journal of the Moffitt Cancer Cen [Category] 진단, [키워드] Anti-spike anti-Spike IgG antibodies antibody COVID-19 COVID-19 infection Critical hematologic malignancies Hematologic malignancy highlight IgG Immunocompromised patients immunogenicity mRNA vaccine Patient Post-vaccine report semi-quantitative Sery spike vaccination [DOI] 10.1177/10732748211070720 PMC 바로가기 [Article Type] Case Reports
Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19강력한 체액성 및 세포성 면역 반응 및 경증 COVID-19 무증상에서 최소 8개월 후 재감염 위험 낮음Article Published on 2022-01-012022-09-11 Journal: Journal of internal medicine [Category] SARS, 진단, 치료기술, [키워드] 95% CI acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 analyzed anti-Spike IgG anti-spike IgG antibodies Anti-spike IgG antibody Asymptomatic asymptomatic to mild Cell Cellular immune response Chain Reaction Cohort coronavirus COVID-19 COVID-19 disease severity COVID-19 patient COVID-19 patients cumulative cumulative incidence detectable immune response Follow-up HCW healthcare worker hospitalized COVID-19 patients humoral Humoral response immune responses incidence Inclusion Infection initial investigated long-term immunity majority memory T memory T cell Mild PCR PCR-confirmed polymerase chain polymerase chain reaction positive positive individual protective effect reduced risk Reinfection remained respiratory response resulting risk SARS-CoV-2 SARS-COV-2 infection seroconverted seronegative seropositive severe acute respiratory syndrome Coronavirus Severe infection spike IgG Support T cell T cell responses vaccination [DOI] 10.1111/joim.13387 PMC 바로가기 [Article Type] Article
Immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 with 12-dose vials: An interim analysisResearch article Published on 2022-01-012022-10-05 Journal: Vaccine [Category] SARS, 비임상, [키워드] Administered administration adopted adverse events affecting age anti-SARS-CoV-2 anti-Spike IgG Anti-spike RBD IgG antibody average BMI ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine correlation dose Effectiveness exhibited Factor female females finding first dose immune response Immunity immunogenicity incidence of COVID-19 Infection injection interim analysis IQR male median Multiple-dose neutralising neutralising antibody participant positive Primary outcome RBDReceptor Binding Domain receiving Receptor binding domain recipient SARS-CoV-2 secondary outcome Side effects sVNT Test the vaccine Vaccine virus Volume [DOI] 10.1016/j.vaccine.2021.12.023 [Article Type] Research article
Immunogenicity of SARS-CoV-2 vaccination in rituximab-treated patients: Effect of timing and immunologic parameters리툭시맙 치료 환자에서 SARS-CoV-2 백신 접종의 면역원성: 시기 및 면역학적 매개변수의 영향Article Published on 2022-01-012022-09-12 Journal: Clinical immunology (Orlando, Fla.) [Category] MERS, SARS, 진단, [키워드] anti-SARS-CoV-2 anti-Spike IgG antibody asked Autoimmune diseases B cell B cells Characteristics correlated COVID-19 Effect Hypogammaglobulinemia IgG IgM immune immune response immune system immunogenicity impair median time medications parameter Patient pre-vaccination recruited reduce reduced respond responses Rheumatic diseases rituximab RTX SARS-CoV-2 vaccination shown significantly therapeutic option therapy titers of IgG treated patient vaccination Vaccines [DOI] 10.1016/j.clim.2021.108897 PMC 바로가기 [Article Type] Article
Longitudinal Analysis of Antibody Responses to the mRNA BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis: A 6-Month Follow-UpMedicine Published on 2021-12-242022-10-31 Journal: Frontiers in Medicine [Category] COVID-19, [키워드] age-matched control analyzed anti-spike antibody anti-Spike IgG BNT162b2 boost Chronic hemodialysis close monitoring Cohort cohort analysis collected Control correlated COVID-19 COVID-19 infection dose ELISA exclusion Factor first dose fraction Hemodialysis hepatitis B higher risk IgA level IgG IgG level IgM immunosuppressive therapy lack longitudinal Lower maintenance mRNA BNT162b2 of BNT162b2 outcomes participant Patient patients performed persistence quantified receive Responder response resulting SARS-CoV-2 second dose sera Seroconversion seroconvert Seronegativity specific antibody vaccination Vaccine vaccine dose Vaccines while [DOI] 10.3389/fmed.2021.796676 PMC 바로가기 [Article Type] Medicine
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial영국에서 2 가지 용량의 Chadox1 NCOV-19 또는 BNT162B2에 따른 3 가지 용량 (부스터)으로서 7 개의 코비드 -19 백신의 안전성 및 면역 원성Clinical Trial Published on 2021-12-182022-08-13 Journal: Lancet (London, England) [Category] Fulltext, SARS, 임상, [키워드] 95% CI Ad26 Ad26.COV2.S adverse event age anti-Spike IgG antibody assigned blinded BNT BNT162b2 booster booster vaccination booster vaccines cellular response Cellular responses ChAd ChAdOx1 ChAdOx1 nCoV-19 Control control group control groups Course COV-BOOST COVID-19 COVID-19 vaccine CureVac CVn CVnCoV dose eligibility criteria ELISA female finding FIVE funding generate geometric mean geometric mean ratio geometric mean ratios GMR GMRs group humoral Humoral and cellular responses immunogenicity individuals initial intention-to-treat population investigated IQR ISRCTN janssen laboratory-confirmed SARS-CoV-2 infection Local m1273 median age MenACWY meningococcal conjugate vaccine Moderna modified intention-to-treat mRNA1273 multicentre neutralising response neutralising responses Novavax NVX NVX-CoV2373 Older Older age outcome Pain participant Participants Pfizer Phase 2 phase 2 trial primary analysis quadrivalent meningococcal conjugate vaccine randomised Randomly ranged reactogenicity referred to Registered Safety SARS-COV-2 infection screened secondary Secondary outcomes Serious Adverse Events Seven spike IgG systemic adverse events the median three group three groups treat treatment allocation Trial Vaccine vaccine availability Valneva Viral viral neutralisation VLA2001 were assessed were blinded white wild-type [DOI] 10.1016/S0140-6736(21)02717-3 PMC 바로가기 [Article Type] Clinical Trial
Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months6개월 동안 BNT162b2 Covid-19 백신에 대한 면역 체액 반응 약화Article Published on 2021-12-092022-09-12 Journal: The New England Journal of Medicine [Category] Fulltext, MERS, 진단, [키워드] 95% CI 95% confidence interval acute respiratory syndrome age analyses anti-Spike IgG antibody BNT162b2 BNT162b2 vaccine conducted coronavirus correlated correlation Coverage decrease determine dose Effectiveness Health care worker humoral IgG IgG antibody Immunosuppression incidence Infection less linear means men Month Neutralizing antibodies neutralizing antibody Neutralizing antibody titer Older participant Participants predictor Prospective Study response SARS-CoV-2 second dose Spearman symptomatic infection tested Vaccine vaccine dose waning immunity were used women [DOI] 10.1056/NEJMoa2114583 PMC 바로가기 [Article Type] Article
Humoral protection to SARS-CoV2 declines faster in patients on TNF alpha blocking therapiesSARS-CoV2에 대한 체액 보호는 TNF 알파 차단 요법을 받는 환자에서 더 빨리 감소합니다Article Published on 2021-12-012022-09-11 Journal: RMD Open [Category] 변종, 진단, [키워드] Anti-spike anti-Spike IgG anti-TNF Antigen appearance Arthritis blockade booster booster vaccination booster vaccinations CD4+ T cell CD4+ T-cell chronic inflammatory disease chronic inflammatory diseases clinically Cohort controls COVID-19 Critical Decline declined Efficacy faster Frequency greater groups healthy controls healthy individual humoral immune response Humoral response humoral responses IgA level IgA levels IgG immune responses Inflammatory diseases lack mRNA vaccination Necrosis neutralization Neutralizing antibodies no differences pandemic Patient patients persistence receiving regimens response SARS-CoV2 second vaccination significantly T cell therapy TNF TNF alpha Treatment Tumor tumor necrosis tumor necrosis factor tumor necrosis factor inhibitors vaccination vaccine response vaccine responses variants while [DOI] 10.1136/rmdopen-2021-002008 PMC 바로가기 [Article Type] Article
Kidney transplant recipients vaccinated before transplantation maintain superior humoral response to SARS-CoV-2 vaccine이식 전에 예방 접종을 받은 신장 이식 환자는 SARS-CoV-2 백신에 대해 우수한 체액 반응을 유지합니다.Article Published on 2021-12-012022-09-12 Journal: Clinical transplantation [Category] SARS, 진단, [키워드] analyzed anti-spike antibody anti-Spike IgG BNT162b2 Candidates Cohort Control COVID-19 develop dialysis healthcare healthy individuals humoral kidney transplant recipient kidney transplant recipients Kidney transplantation Lymphocyte count maintain negative Odds ratio Older age Patient Pfizer-BioNTech positive serology Protective recipient recommendation SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine Serologic response seropositive significantly lower Support sustained the patient vaccination Vaccine [DOI] 10.1111/ctr.14478 PMC 바로가기 [Article Type] Article
Functional convalescent plasma antibodies and pre-infusion titers shape the early severe COVID-19 immune response기능적 회복기 혈장 항체 및 주입 전 역가는 초기 중증 COVID-19 면역 반응을 형성합니다Article Published on 2021-11-252022-09-10 Journal: Nature Communications [Category] MERS, SARS, 유전자 메커니즘, 임상, 진단, 치료기술, 치료법, [키워드] administration Anti-nucleocapsid antibodies anti-nucleocapsid antibody Anti-spike anti-Spike IgG antibodies antibody Antibody titer binding convalescent plasma Evolution function functional heterogeneous nature heterogenous hospitalized COVID-19 patient hospitalized COVID-19 patients humoral humoral immune responses Humoral immunity Humoral response humoral responses immune immune response immune responses modulation nucleocapsid-specific antibody outcomes pandemic Patient plasma profile Receptor binding recipient SARS-CoV-2 SARS-CoV-2 nucleocapsid SARS-CoV-2 pandemic severe COVID-19 Severe infection Symptoms the SARS-CoV-2 therapy transfer Translational immunology Trial viral infection [DOI] 10.1038/s41467-021-27201-y PMC 바로가기 [Article Type] Article